Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 9/20 | 0.80 |
| ▸ | KMT2A | Q03164 | 7/20 | 0.80 |
| ▸ | MEN1 | O00255 | 6/20 | 0.80 |
| ▸ | POLB | P06746 | 5/20 | 0.80 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.80 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.80 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.54 |
| ▸ | LMNA | P02545 | 3/20 | 0.54 |
| ▸ | HTT | P42858 | 3/20 | 0.54 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.53 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.53 |
| ▸ | CAPN9 | O14815 | 1/20 | 0.52 |
| ▸ | CASP3 | P42574 | 1/20 | 0.52 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.47 |
| ▸ | HTR1A | P08908 | 1/20 | 0.47 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.47 |
| ▸ | DRD1 | P21728 | 1/20 | 0.47 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.47 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.47 |
| ▸ | DRD3 | P35462 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30181459 | 0.99 | MAPT (0.78) | MAPTKMT2AMEN1POLBL3MBTL1 | |
| Ammonia Solution, Strong SCHEMBL23835580 | 0.99 | MAPT (0.78) | MAPTKMT2AMEN1POLBL3MBTL1 | |
| SCHEMBL13437129 | 0.84 | MAPT (0.57) | MAPTKMT2AMEN1POLBL3MBTL1 | |
| SCHEMBL2113066 | 0.83 | ALDH1A1 (0.56) | MAPTKMT2AMEN1POLBL3MBTL1 | |
| SCHEMBL13436776 | 0.83 | MAPT (0.60) | MAPTKMT2AMEN1POLBL3MBTL1 | |
| SCHEMBL15679893 | 0.82 | MAPT (0.58) | MAPTKMT2AMEN1POLBL3MBTL1 | |
| SCHEMBL30811587 | 0.81 | MAPT (0.72) | MAPTKMT2AMEN1POLBL3MBTL1 | |
| SCHEMBL21628256 | 0.81 | MAPT (0.72) | MAPTKMT2AMEN1POLBL3MBTL1 | |
| SCHEMBL29636451 | 0.81 | MAPT (0.72) | MAPTKMT2AMEN1POLBL3MBTL1 | |
| Phenoxazine SCHEMBL27280590 | 0.79 | MAPT (0.65) | MAPTKMT2AMEN1POLBL3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260102407-A1 | TREATMENT METHODS | KHACHIGIAN LEVON MICHAEL (AU) | 2026-04-16 | — | — | US | disclosed |
| US-20240050444-A1 | TREATMENT METHODS | VASCULAR THERAPEUTICS PTY LTD (AU) | 2024-02-15 | — | — | US | disclosed |
| EP-4117655-A1 | TREATMENT METHODS | Khachigian, Levon, Michael (AU) | 2023-01-18 | — | — | EP | disclosed |
| WO-2021184059-A1 | TREATMENT METHODS | NEWSOUTH INNOVATIONS PTY LIMITED (AU) | 2021-09-23 | — | — | WO | disclosed |
| US-20080275023-A1 | N-Hydroxyamides Omege-Substituted with Tricyclic Groups as Histone Deacetylase Inhibitors, Their Preparation and Use in Pharmaceutical Formulations | MENARIN INTERNATIONAL OPERATIONS LUXEMBOURG S.A. (LU) | 2008-11-06 | — | — | US | disclosed |
| US-7410975-B2 | Small molecule toll-like receptor (TLR) antagonists | COLEY PHARMACEUTICAL GROUP, INC. (US) | 2008-08-12 | — | — | US | disclosed |
| EP-1863776-A1 | N-HYDROXYAMIDES OMEGA-SUBSTITUTED WITH TRICYCLIC GROUPS AS HISTONE DEACETYLASE INHIBITORS, THEIR PREPARATION AND USE IN PHARMACEUTICAL FORMULATIONS | Menarini International Operations Luxembourg S.A. (LU) | 2007-12-12 | — | — | EP | disclosed |
| US-20070232622-A1 | Small molecule toll-like receptor (TLR) antagonists | COLEY PHARMACEUTICAL GMBH (DE) | 2007-10-04 | — | — | US | disclosed |
| WO-2006097449-A1 | N-HYDROXYAMIDES OMEGA-SUBSTITUTED WITH TRICYCLIC GROUPS AS HISTONE DEACETYLASE INHIBITORS, THEIR PREPARATION AND USE IN PHARMACEUTICAL FORMULATIONS | MENARINI INTERNATIONAL OPERATIONS LUXEMBOURG S.A. (LU) | 2006-09-21 | — | — | WO | disclosed |
| US-6919328-B1 | Tricyclic compounds with NOS activity | NEURAXON INC. (CA) | 2005-07-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240050444-A1 | TREATMENT METHODS | FOSB, FOS, VCAM1 | MAPT 2602/4885KMT2A 4344/4885MEN1 4247/4885 |
| US-20070232622-A1 | Small molecule toll-like receptor (TLR) antagonists | TLR3, TLR8, TLR7 | MAPT 3823/4885KMT2A 899/4885MEN1 3966/4885 |
| US-20260102407-A1 | TREATMENT METHODS | FOSB, VCAM1, FOS | MAPT 3149/4885KMT2A 4507/4885MEN1 2796/4885 |
| US-20080275023-A1 | N-Hydroxyamides Omege-Substituted with Tricyclic Groups as Histone Deacetylase Inhibitors, Their Preparation and Use in Pharmaceutical Formulations | HDAC8, HDAC2, HDAC7 | MAPT 2847/4885KMT2A 45/4885MEN1 3533/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.